New Year’s Day price hikes on block­buster drugs set the stage for a big de­bate

7 years ago
Bioregnum
Opinion

The 2018 break­down on a chart-top­ping set of new drug ap­provals — and the 5 big things we learned from it

7 years ago
Special
Pharma

Next-gen T cell play­er TCR2 Ther­a­peu­tics sets stage for $100M-plus IPO as MP­M's Baeuer­le caps pro­lif­ic year

7 years ago
Financing

Backed by a pi­o­neer in BiTE tech, Har­poon marks a course for an IPO and an ear­ly dis­play of po­ten­tial

7 years ago
Financing

Chi­na green­lights sec­ond home­grown PD-1 in 10 days as In­novent cel­e­brates its first drug OK with Eli Lil­ly

7 years ago
China
Pharma

Lit­tle Capri­cor hits the brakes on a stem cell tri­al for Duchenne MD fol­low­ing an al­ler­gic re­ac­tion

7 years ago
R&D

What oth­er biotech news have you been miss­ing? A big Chi­na IPO and more

7 years ago
Financing
China

Fledg­ling Gos­samer sets up an ear­ly biotech IPO test for 2019 with a $265M chal­lenge

7 years ago
Financing

Acor­da cel­e­brates an FDA OK — so does that make them a takeover tar­get?

7 years ago
Pharma

FDA hits a green light on 2 more rare dis­ease drugs, giv­ing Alex­ion an ear­ly shot at pro­tect­ing PNH fran­chise

7 years ago
Pharma

Pfiz­er, Mer­ck KGaA hit the brakes on an­oth­er PhI­II as PD-L1 Baven­cio flops yet again

7 years ago
R&D

Can No­var­tis slim down CAR-T man­u­fac­tur­ing time­lines with its lat­est ac­qui­si­tion at­tempt?

7 years ago
Deals

Col­in Fre­und takes new CEO job at Mod­ra Phar­ma; Com­pass re­cruits Pfiz­er, Bio­gen vets to C-suite

7 years ago
Peer Review

The top 10 sto­ries from End­points News in 2018

7 years ago
Special

Biotech bil­lion­aire Hi­roshi ‘Mick­ey’ Mik­i­tani dou­bles down on quest to build a phar­ma com­pa­ny, clos­ing round at ...

7 years ago
Financing

No­var­tis' SMA gene-ther­a­py, if priced at $2M, could be more cost-ef­fec­tive than Bio­gen's Spin­raza — ICER

7 years ago
Pharma
Cell/Gene Tx

Boehringer of­floads an mTOR can­cer drug as Xy­nom­ic plots a quick ad­vance in the clin­ic

7 years ago
R&D
Pharma

Cash, pipeline-rich Io­n­is gives COO Mo­nia top job in 2020, as founder and chief Crooke tran­si­tions to board chair­man

7 years ago
People

G1 touts PhII can­cer da­ta, but shares tank on place­bo re­sults; Mer­ck bags an­oth­er ap­proved in­di­ca­tion for Keytru­da

7 years ago
News Briefing

On the heels of Chi­na ap­proval, Fi­bro­Gen and As­traZeneca spot­light more pos­i­tive PhI­II da­ta for rox­adu­s­tat

7 years ago
R&D

Mer­ck KGaA hands off its CAR-T R&D op­er­a­tions to In­trex­on in $175M deal

7 years ago
R&D

Cash-poor Agenus finds it­self a gen­er­ous part­ner in Gilead, shares surge

7 years ago
Pharma

Google’s GV en­lists ma­chine learn­ing pro Rosana Kapeller in its dri­ve to cre­ate a new breed of biotech

7 years ago
People

As with chil­dren stud­ies, Su­per­nus AD­HD drug shows fast on­set of ac­tion in ado­les­cents

7 years ago
R&D
First page Previous page 986987988989990991992 Next page Last page
A service from the Financial Times